US 12,290,570 B2
Antibody comprising a glutamine-containing light chain C-terminal extension, conjugates thereof, and methods and uses
Pavel Strop, San Mateo, CA (US); Chetana Rao-Naik, Walnut Creek, CA (US); Xiaodi Deng, San Mateo, CA (US); Paul O. Sheppard, Granite Falls, WA (US); Patrick G. Holder, Piedmont, CA (US); and Sayumi Yamazoe, Mountain View, CA (US)
Assigned to BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US)
Appl. No. 17/297,796
Filed by BRISTOL-MYERS SQUIBB COMPANY, Princeton, NJ (US)
PCT Filed Nov. 25, 2019, PCT No. PCT/US2019/062913
§ 371(c)(1), (2) Date May 27, 2021,
PCT Pub. No. WO2020/112588, PCT Pub. Date Jun. 4, 2020.
Claims priority of provisional application 62/773,708, filed on Nov. 30, 2018.
Prior Publication US 2022/0016260 A1, Jan. 20, 2022
Int. Cl. A61K 47/68 (2017.01); C07K 16/18 (2006.01)
CPC A61K 47/6851 (2017.08) [A61K 47/6811 (2017.08); C07K 16/18 (2013.01)] 23 Claims
 
1. A full length antibody having on the C-terminus of a light chain thereof a glutamine-containing extension comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1, NO: 2, NO: 3, NO: 4, NO: 5, NO: 6, NO: 7, NO: 8, NO: 9, NO: 10, NO: 11, NO: 12, NO: 13, NO: 14, NO: 15, NO: 16, NO: 17, NO: 18, NO: 19, NO: 20, NO: 21, NO: 22, NO: 23, NO: 24, NO: 25, NO: 26, NO: 29, NO: 30, NO: 31, NO: 32, NO: 33, NO: 34, NO: 35, NO: 36, NO: 37, NO: 38, NO: 39, and NO: 40.